Why can live vaccines increase the risk of severe infections during pegaspargase treatment?

Live vaccines during pegaspargase (Oncaspar) treatment may increase severe infection risk because of pegaspargase’s immunosuppressive activity, the underlying disease and combination chemotherapy; live vaccination should wait until at least 3 months after all antileukaemic treatment ends.